Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version
Antibodies Assay Kits Biology Cells cDNA Clia Kits Culture Cells Devices DNA DNA Templates DNA Testing Elisa Kits Enzymes Equipments Exosomes Gels Isotypes Medium & Serums NATtrol Panel Particles PCR Pcr Kits Peptides Reagents Recombinant Proteins Ria Kits RNA Test Kits Vector & Virus Western Blot
December 9, 2020

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

By Matsuoka
Background: The rise within the variety of most cancers circumstances and the evolution of most cancers care administration have turn out to be a big downside for the French well being care system, thereby making affected person empowerment as a protracted sought-after purpose in continual pathologies. The implementation of an activation measure through the Affected person Activation Measure-13 merchandise (PAM-13) in the midst of most cancers care can probably spotlight the affected person’s wants, with nursing care adapting accordingly.
Goal: The goals of this PARACT (PARAmedical Interventions on Affected person ACTivation) multicentric research have been as follows: (1) consider the implementation of PAM-13 in oncology nursing practices in 5 complete most cancers facilities, (2) determine the obstacles and facilitators to the implementation of PAM-13, and (3) produce suggestions for the dissemination of such interventions in different complete most cancers facilities.
Strategies: This research will comply with the “Attain, Effectiveness, Adoption, Implementation, and Upkeep” framework and can consist of three phases. First, a strong preimplementation evaluation will probably be performed utilizing the Theoretical Domains Framework (TDF) linked to the “Functionality, Alternative, Motivation, and Conduct” mannequin to determine the obstacles and facilitators to implementing new nursing practices in every context. Then, utilizing the Conduct Change Wheel, we are going to personalize a technique for implementing the PAM-13, relying on the specificities of every context, to encourage acceptability by the nursing employees concerned within the mission. This evaluation will probably be carried out through a qualitative research by way of semistructured interviews.
Second, the affected person will probably be included within the research for 12 months, throughout which the affected person care pathway will probably be studied, significantly to gather all related contacts of oncology nurses and different well being professionals concerned within the pathway. The axes of nursing care may even be collected. The first purpose is to implement PAM-13. Secondary elements to be measured are the affected person’s nervousness stage, high quality of life, and well being literacy stage. The oncology nurses will probably be liable for finishing the questionnaires when the affected person is on the hospital for his/her intravenous chemotherapy/immunotherapy remedy. The questionnaires will probably be accomplished thrice in a 12 months: (1) on the time of the affected person’s enrollment, (2) at 6 months, and (3) at 12 months. Third, a postimplementation evaluation will probably be carried out by way of semistructured interviews utilizing the TDF to research the implementation issues at every website.
Outcomes: This research was supported by a grant from the French Ministry of Well being (PHRIP PARACT 2016-0405) and the Lucien Neuwirth Institute of Cancerology of Saint-Etienne, France. Knowledge assortment for this research is ongoing.
Conclusions: This research would enhance the carried out focused nursing interventions in most cancers facilities so {that a} affected person is obtainable a customized most cancers care pathway. Moreover, measuring the extent of activation and the implementation of measures meant to extend such activation may represent a big benefit in decreasing social well being inequalities.

Navigating uncharted waters: Creating a standardized method for evaluating and implementing biosimilar merchandise at a complete most cancers middle

Goal: The processes for formulary implementation and digital well being file (EHR) integration of biosimilar merchandise at a complete most cancers middle are described. Implications for analysis protocols are additionally mentioned.
Abstract: The present literature focuses on sensible concerns for formulary addition of biosimilar merchandise, however there’s a lack of steering on how you can implement the change, significantly throughout the EHR. Earlier than constructing the ordering instruments for biosimilars, the scientific and informatics groups ought to decide the function of biosimilars on the establishment, determine drug-specific product traits that have an effect on treatment construct, and characterize implications of future formulary adjustments or drug shortages. Leveraging an orderable file supplies the power to incorporate logic that maps to a number of merchandise and in addition permits for future implementation of adjustments throughout the treatment file fairly than requiring “swaps” on the remedy protocol stage. The institutional overview board ought to coordinate adjustments in affected analysis protocols and consent kinds and work with principal investigators to amend protocols when obligatory. Pharmacy leaders ought to develop processes to supervise stock in the course of the transition interval and decrease the chance of errors.
Conclusion: The event of a standardized method for evaluating and implementing biosimilar merchandise improves effectivity and collaboration among the many numerous group members liable for the merchandise’ integration into present workflows, together with implications for scientific analysis. Implementing biosimilars for brokers used to deal with most cancers will pose new challenges and require extra concerns. Partial implementation of biosimilars continues to pose a number of challenges within the provision of affected person care.
Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

Effect of PARACT (PARAmedical Interventions on Patient ACTivation) on the Cancer Care Pathway: Protocol for Implementation of the Patient Activation Measure-13 Item (PAM-13) Version

Matrix stiffness epigenetically regulates the oncogenic activation of the Sure-associated protein in gastric most cancers

In lots of cancers, tumour development is related to elevated tissue stiffness. But, the mechanisms associating tissue stiffness with tumorigenesis and malignant transformation are unclear. Right here we present that in gastric most cancers cells, the stiffness of the extracellular matrix reversibly regulates the DNA methylation of the promoter area of the mechanosensitive Sure-associated protein (YAP). Reciprocal interactions between YAP and the DNA methylation inhibitors GRHL2, TET2 and KMT2A may cause hypomethylation of the YAP promoter and stiffness-induced oncogenic activation of YAP.

Human Cancer PrimaCell4: Breast Tumor Cells Growth Medium
9-46027 5 x 100 ml Ask for price

Breast Cancer-Associated Antigen BRCAA1 (BRCAA1) Antibody
20-abx148333
  • EUR 510.00
  • EUR 410.40
  • 100 ug
  • 50 ug

Human Cancer Tissue Preparation Buffer 4: Breast Tumor Cells
9-80027 1 x 100 ml Ask for price

Breast cancer and normal tissue array with stage and grade info
BR8012 each
EUR 306
Description: Breast cancer and normal tissue array with stage and grade info, 40 cases/80 cores, replaced by BR8014

Human tumor marker CA549 for breast cancer ELISA Kit
SL3271Hu 96 Tests
EUR 468

BSA (Standard Grade)
30-AB70 1 kg
EUR 1078.8
Description: Standard Grade Bovine Serum Albumin (99% pure)

Gastrointestinal Cancer Antigen (CA 19-9), antigen grade
CA1991-N-10 10 KU
EUR 634.8

Breast Cancer and 8 types of tumor (middle advanced stage)tissue array
BR20838a each
EUR 474
Description: Breast Cancer and 8 types of tumor (middle advanced stage)tissue array, including pathology grade, TNM/stage with IHC Her-2 results, 118 cases/208 cores (core size 1.5mm), replacing BR20838

Breast cancer
BR1008b each
EUR 306
Description: Breast cancer, lymph node metastatic carcinoma and adjacent normal tissue array, including pathology grade, TNM, clinical stage, and ER/PR/Her2 result, 100 cases/100 cores, replacing BR1008a

Breast cancer
BR724 each
EUR 270
Description: Breast cancer, adjacent and adjacent normal tissue array, 66 cases/72 cores

Breast cancer
BR725 each
EUR 270
Description: Breast cancer, adjacent and adjacent normal tissue array, 68 cases/72 cores

Breast cancer with cancer adjacent breast tissue array
BC081116e each
EUR 306
Description: Breast cancer with cancer adjacent breast tissue array, including invasive carcinoma of no special type, breast carcinoma with apocrine differentiation and AT tissue,pat hology grade, IHC (ER/PR/Her-2/Ki67) info, TNM/Stage (AJCC 7th edition), 107 cases/110 cores (core size 1.5mm), replacing BC081116d

Breast Tumor Tissue Array - 16 cases of breast cancer, each in duplicates, paired with adjacent normal tissues
Z7020007 5 slides
EUR 1657.2
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Circulating tumor cell breast cancer detection kit (anti-HER-2 Ab Magbeads)
E601CM003 20 tests
EUR 2500

CancerSeq™ Paraffin Tissue Tumor Block: Breast
T2235086-SB 1 Block
EUR 4014

Breast cancer TMA
BR602 each
EUR 270
Description: Breast cancer TMA, 3 samples have matched cancer adjacent tissue samples, including pathology grade, TNM and clinical stage (reference AJCC 8th version), 57 cases/60 cores (Core Size 1.5mm), recent tear collections

CancerSeq™ Paraffin Tissue Tumor Slides: Breast
T2235086-ST 5 Slides
EUR 572

Breast cancer with matched cancer adjacent breast tissue array
BR804b each
EUR 306
Description: Breast cancer with matched cancer adjacent breast tissue array, including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2 and Ki67), 40 cases/80 cores, replacing BR804a

Breast cancer with breast tissue array
BC08118a each
EUR 258
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 100 cases/100 cores (core size 1.0mm), replacing BC08118

Breast cancer with breast tissue array
BR2085d each
EUR 546
Description: Breast cancer with breast tissue array, including pathology grad, TNM and clinical stage, 188 cases/208 cores, replacing BR2085c

Breast cancer with breast tissue array
BR246d each
EUR 66
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage (reference AJCC 7th version), 12 cases/24 cores, replacing BR246c

Breast cancer with breast tissue array
BR482 each
EUR 198
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 24 cases/48 cores

Breast cancer with breast tissue array
BR720 each
EUR 270
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical satge (reference AJCC 7th version), 72 cases/72 cores

Breast cancer with breast tissue array
T087d each
EUR 66
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T087c

Breast cancer with breast tissue array
T088d each
EUR 66
Description: Breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T088c

Breast Cancer Exosome
P141-BR - Ask for price

Breast Tumor Tissue Array - duplicated 70 cases covering all the common types of breast cancer and 5 cases of normal and
Z7020004 5 slides
EUR 1293

Breast Tumor Tissue Array - Duplicated 70 cases covering all the common types of breast cancer and 5 cases of normal and
Z7020005 5 slides
EUR 1293

Breast Tumor Tissue Array - Duplicated 36 cases covering all the common types of breast cancer and 12 cases of normal an
Z7020008 5 slides
EUR 1657.2
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Breast Tumor Tissue Array - Duplicated 36 cases covering all the common types of breast cancer and 12 cases of normal an
Z7020009 5 slides
EUR 1657.2
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool.

Human Cancer PrimaCell4: Breast Tumor Cells Growth Supplements with Serum (for 500 ml medium)
9-47027 1 Set Ask for price

CancerSeq™ Plus Paraffin Tissue Tumor Sections: Breast
T2235086-SC 5 curls
EUR 779

Breast cancer tissue array with cancer adjacent breast tissue as control
BR208a each
EUR 474
Description: Breast cancer tissue array with cancer adjacent breast tissue as control, including TNM, clinical stage and pathology grade, 69 cases/ 207 cores.

Breast cancer (including one case of male breast cancer) with adjacent normal breast tissue array
BC081120g each
EUR 306
Description: Breast cancer (including one case of male breast cancer) with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage (AJCC 7th edition) with IHC results ER/PR/Her2/Ki67,110 cases/110 cores (core size 1.0 mm), replacing BC081120f

Proteinase K, Recombinant, Standard Grade
9250-100 each
EUR 124.8

Proteinase K, Recombinant, Standard Grade
9250-10G each
EUR 4627.2

Proteinase K, Recombinant, Standard Grade
9250-1G each
EUR 548.4

Proteinase K, Recombinant, Standard Grade
9250-500 each
EUR 314.4

Proteinase K, Recombinant, Standard Grade
9251-100 each
EUR 1266

Proteinase K, Recombinant, Standard Grade
9251-25 each
EUR 352.8

Proteinase K, Recombinant, Standard Grade
9251-5 each
EUR 144

Breast cancer with matched breast tissue array
BR251e each
EUR 60
Description: Breast cancer with matched breast tissue array, including pathology grade, IHC info (ER,PR,Her-2,Ki67),TNM\Stage, 6 cases/24 cores (core size 1.5mm), replacing BR251d

Breast Cancer Exosome RNA
P241-BR - Ask for price

Multiple breast cancer with breast tissue array
BR087e each
EUR 48
Description: Multiple breast cancer with breast tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing BR087d

Breast cancer tissue array
BR042b each
EUR 78
Description: Breast cancer tissue array, including TNM and pathology grade, 4 cases/4 cores, replacing BR042a

Breast cancer tissue array
BR1006a each
EUR 306
Description: Breast cancer tissue array, including pathology grade, TNM and clinical stage, 50 cases/100 cores (core size 1.0mm), replacing BR1006

Breast cancer tissue array
BR1141a each
EUR 354
Description: Breast cancer tissue array, including pathology grade, TNM and clinical stage, IHC marker (ER, PR, HER2 and Ki-67), 114 cases/114 cores, replacing BR1141

Breast cancer tissue array
BR1401 each
EUR 414
Description: Breast cancer tissue array, including TNM and pathology grade, IHC markers ER/PR/Her-2 results, 140 cases/140 cores (core size 1.0mm)

Breast cancer tissue array
BR1503f each
EUR 306
Description: Breast cancer tissue array, including TNM and pathology grade, with IHC results of Her-2\ER\PR\Ki67, 75 cases/ 150 cores, replacing BR1503e

Breast cancer tissue array
BR1505e each
EUR 306
Description: Breast cancer tissue array, including pathology grade, TNM, clinical stage, and IHC(HER2/ER/PR/Ki67), 75 cases/150 cores, replacing BR1505d

Breast cancer tissue array
BR2161 each
EUR 546
Description: Breast cancer tissue array, including TNM and pathology grade, 216 cases/216 cores

Breast cancer tissue array
BR247a each
EUR 234
Description: Breast cancer tissue array, with normal tissue, including TNM and pathology grade, IHC marker (HER2), 24 cases/48 cores replacing BR247

Breast cancer tissue array
BR488 each
EUR 306
Description: Breast cancer tissue array, including pathology grade, TNM, clinical stage (AJCC 7th edition), and IHC marker(ER,PR,Her-2), 48 cases/48 cores

Breast cancer tissue array
BR501 each
EUR 270
Description: Breast cancer tissue array, including TNM and pathology grade, 50 cases/ 50 cores (core size 1.5mm)

Breast cancer tissue array
BR8015a each
EUR 306
Description: Breast cancer tissue array, with adjacent normal tissue and normal tissue, including TNM and pathology grade, 80 cases/80 cores, replacing BC08014

Breast cancer tissue array
BR964 each
EUR 222
Description: Breast cancer tissue array, including TNM, clinical stage and pathology grade, 48 cases/96 cores

Breast cancer tissue array
T089c each
EUR 48
Description: Breast cancer tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores(1.5mm), replacing T089b

Advanced stage breast cancer and normal breast tissue array
BR1191 each
EUR 306
Description: Advanced stage breast cancer and normal breast tissue array, including pathology grade, TNM and clinical stage (AJCC 8.0), ER\PR\HER-2\Ki-67 marker, 119 cases/119 cores, (1.5mm)

Breast normal tissue with breast cancer tissue array
BRN801c each
EUR 270
Description: Breast normal tissue with breast cancer tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing BRN801b

Standard grade heat shock BSA powder, pH 7
BAH62-0050 50gm
EUR 308.88

Standard grade heat shock BSA powder, pH 7
BAH62-0100 100gm
EUR 388.44

Standard grade heat shock BSA powder, pH 7
BAH62-0500 500gm
EUR 511.68

Standard grade heat shock BSA powder, pH 7
BAH62-1000 1KG Ask for price

Standard grade heat shock BSA powder, pH 7
BAH62-10000 10KG Ask for price

Standard grade heat shock BSA powder, pH 5.2
BAH63-0050 50gm
EUR 308.88

Standard grade heat shock BSA powder, pH 5.2
BAH63-0100 100gm
EUR 388.44

Standard grade heat shock BSA powder, pH 5.2
BAH63-0500 500gm
EUR 511.68

Standard grade heat shock BSA powder, pH 5.2
BAH63-1000 1KG Ask for price

Standard grade heat shock BSA powder, pH 5.2
BAH63-10000 10KG Ask for price

Breast cancer with adjacent normal breast tissue array
BR1921c each
EUR 546
Description: Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM, clinical stage and IHC marker (ER, PR and Her-2), 189 cases/192 cores, replacing BR1921b

Breast cancer with adjacent normal breast tissue array
BR803c each
EUR 258
Description: Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage, 80 cases/80 cores, replacing BR803b

Breast cancer with adjacent normal breast tissue array
BR901a each
EUR 270
Description: Breast cancer with adjacent normal breast tissue array, including pathology grade, TNM and clinical stage, 45 cases/90 cores, replacing BR901

Breast Cancer Anti-Estrogen Resistance 1
PR27245 2 ug
EUR 229.2

Breast cancer test tissue array
T086e each
EUR 66
Description: Breast cancer test tissue array, including TNM, clinical stage and pathology grade, 12 cases/24 cores, replacing T086d

Bovine Serum Albumin, Fraction V - Standard Grade
22070008-1 25 g
EUR 44.19
Description: BSA

Bovine Serum Albumin, Fraction V - Standard Grade
22070008-2 50 g
EUR 68.62
Description: BSA

Bovine Serum Albumin, Fraction V - Standard Grade
22070008-3 100 g
EUR 127.13
Description: BSA

Bovine Serum Albumin, Fraction V - Standard Grade
22070008-4 250 g
EUR 248.48
Description: BSA

Bovine Serum Albumin, Fraction V - Standard Grade
22070008-5 500 g
EUR 447.06
Description: BSA

Bovine Serum Albumin, Fraction V - Standard Grade
22070008-6 1 kg
EUR 774.79
Description: BSA

Late stage breast cancer tissue array
BR1922 each
EUR 546
Description: Late stage breast cancer tissue array, including TNM, clinical stage and pathology grade, 96 cases/192 cores

Microplate cell grade 96well ps standard
781965 PK50
EUR 410.4

Cancer of the breast, 102 cases (1.5mm)
BRC1021 1
EUR 300
Description: Breast cancer tissue array, 102 cases of normal/benign (5 cases) and cancer (97 cases) tissues, with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.

Cancer of the breast, 228 cases (1.1mm)
BRC2281 1
EUR 552
Description: Breast cancer tissue array containing 8 cases of normal/benign conditions and 220 cases of cancers with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody
20-abx171475
  • EUR 1028.40
  • EUR 526.80
  • 1 mg
  • 200 ug

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody
20-abx324781
  • EUR 376.80
  • EUR 292.80
  • 100 ug
  • 50 ug

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody
20-abx129227
  • EUR 510.00
  • EUR 159.60
  • EUR 1446.00
  • EUR 693.60
  • EUR 393.60
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit
PRB-5069 96 assays
EUR 686.4

Human Cancer Antigen 15-3 (CA 15-3) ELISA Kit
PRB-5069-5 5 x 96 assays
EUR 2739.6

Cancer Antigen 15-3 MUC 1 Antigen (Human Milk)
VAng-Cr3871-10kU 10 kU
EUR 505.2
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Milk. The purity is detected by salt extraction and delipidization following high speed centrifugation. It is tested negative for HBsAg, antibodies to HCV and HIV 1/2.

Breast disease spectrum (breast cancer progression) tissue array
BR2082c each
EUR 546
Description: Breast disease spectrum (breast cancer progression) tissue array, including pathology grade, TNM and clinical stage, IHC marker (ER, PR, HER2 and Ki-67), 186 cases/192 cores, replacing BR2082b

Breast cancer with matched or unmatched breast tissue array
BR802c each
EUR 270
Description: Breast cancer with matched or unmatched breast tissue array, including pathology grade, TNM and clinical stage, 53 cases/80 cores, replacing BR802b

Breast tumor tissue array (15 of 25)
BR20821 each
EUR 474
Description: Breast tumor tissue array (15 of 25), including TNM, clinical stage, pathology grade and IHC markers (ER, PR, Her-2) results,104 cases/208 cores

Breast cancer Exosome Isolation Kit
E601E002 20 tests
EUR 2500

Breast cancer tissue array with adjacent normal breast tissue
BR8011a each
EUR 306
Description: Breast cancer tissue array with adjacent normal breast tissue, including TNM, clinical stage, pathology grade and DCIS, 80 cases/80 cores, replacing BR8011

Cancer of the breast, 75 cases (1.1mm), set 3
BRC1503 1
EUR 300
Description: Breast cancer tissue array, set 3, non-overlapping with BRC1501, BRC1502, BRC1504 to BRC15011,150 cores from normal/benign (5 cases) and cancer (70 cases) tissues in duplicates with grading, TNM staging data, AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.

Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3)
4-RPG768Hu01
  • EUR 601.69
  • EUR 284.40
  • EUR 1926.34
  • EUR 722.11
  • EUR 1324.22
  • EUR 477.60
  • EUR 4635.84
  • 100 ug
  • 10ug
  • 1 mg
  • 200 ug
  • 500 ug
  • 50ug
  • 5 mg
Description: Recombinant Human Breast Cancer Anti-Estrogen Resistance 3 expressed in: E.coli

Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3)
RPU53453-100ug 100ug
EUR 552.2

Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3)
RPU53453-1mg 1mg
EUR 2446.6

Recombinant Breast Cancer Anti-Estrogen Resistance 3 (BCAR3)
RPU53453-50ug 50ug
EUR 443.3

Breast Cancer Metastasis Suppressor 1
PR27265 2 ug
EUR 229.2

Cancer of the breast, 49 cases (2mm)
BRC491 1
EUR 228
Description: Breast cancer tissue array, non-overlapping with BRC711, 49 cases of normal/benign and cancer tissues with grading, TNM staging, and AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.

Cancer of the breast, 71 cases (1.1mm)
BRC711 1
EUR 228
Description: Breast cancer tissue array, non-overlapping with BRC491, 71 cases of normal/benign and cancer tissues with grading, TNM staging data, AR, ER, PR, HER2, P53, EGFR, Ki67 IHC data.

Bovine Serum Albumin ? Heat Shock, Standard Grade, pH 7.0
7915-100 each
EUR 705.6

Bovine Serum Albumin ? Heat Shock, Standard Grade, pH 7.0
7915-25 each
EUR 274.8

Bovine Serum Albumin ? Heat Shock, Standard Grade, pH 7.0
7915-5 each
EUR 144

Bovine Serum Albumin ? Heat Shock, Standard Grade, pH 5.2
7916-100 each
EUR 705.6

Bovine Serum Albumin ? Heat Shock, Standard Grade, pH 5.2
7916-25 each
EUR 274.8

Bovine Serum Albumin ? Heat Shock, Standard Grade, pH 5.2
7916-5 each
EUR 144

Breast Cancer Anti-Estrogen Resistance 1 Protein
20-abx262743
  • EUR 393.60
  • EUR 7676.40
  • EUR 276.00
  • 10 ug
  • 1 mg
  • 2 µg

Vitamin A Reference Standard (USP grade powder)
51R-U716002 10 pack
EUR 619.2
Description: Vitamin A Reference Standard (USP grade powder) chemical reference substance

Breast cancer and normal tissue array
BR485 each
EUR 414
Description: Breast cancer and normal tissue array, including TNM and pathology grade, 2 serial sections, 48 cases/96 cores

Breast cancer and normal tissue array
BR8014 each
EUR 306
Description: Breast cancer and normal tissue array, including TNM, clinical stage and pathology grade, 40 cases/80 cores, replaced by BR8015

Single Donor Human Breast Cancer Serum
ISERSBSC each
EUR 209
Description: Single Donor Human Breast Cancer Serum

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Protein
20-abx168253
  • EUR 844.80
  • EUR 343.20
  • EUR 2598.00
  • EUR 994.80
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 1 mg
  • 200 ug
  • 50 ug

Breast Cancer Cell Protein 2 (BRCC2) Antibody
20-abx141388
  • EUR 444.00
  • EUR 727.20
  • EUR 360.00
  • 100 ul
  • 200 ul
  • 50 ul

Human Serum AB off clot Standard Grade Heat Inactivated
S101BHIEU 100ML
EUR 449.16

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody
20-abx133658
  • EUR 360.00
  • EUR 526.80
  • EUR 226.80
  • 100 ul
  • 200 ul
  • 30 ul

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody
abx025588-400ul 400 ul
EUR 627.6

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody
abx025588-80l 80 µl
EUR 343.2

Breast Cancer-Associated Gene 3 Protein (BCA3) Antibody
20-abx013807
  • EUR 376.80
  • EUR 117.60
  • EUR 477.60
  • EUR 594.00
  • 100 ug
  • 10 ug
  • 200 ug
  • 300 µg

Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody
20-abx134976
  • EUR 427.20
  • EUR 644.40
  • EUR 260.40
  • 100 ul
  • 200 ul
  • 30 ul

Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody
abx218562-100ug 100 ug
EUR 526.8

Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody
abx432398-200ul 200 ul
EUR 460.8

Breast Cancer Anti-Estrogen Resistance Protein 3 (BCAR3) Antibody
abx010337-100ug 100 ug
EUR 526.8

Single Donor Human Breast Cancer Plasma
IPLASBSC each
EUR 209
Description: Single Donor Human Breast Cancer Plasma

Cancer Antigen 15-3 MUC 1 Antigen (Human Ascites Fluid)
VAng-Cr3872-10kU 10 kU
EUR 1363.2
Description: Cancer Antigen 15-3 MUC 1 Antigen, Host/Source: Human Ascites Fluid.

Breast cancer with matched metastatic carcinoma or breast tissue array
BRM961a each
EUR 384
Description: Breast cancer with matched metastatic carcinoma or breast tissue array, including pathology grade, TNM, clinical stage and IHC marker (ER, PR and Her-2), 49 cases/96 cores

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Polyclonal Antibody
CAU22164-100ul 100ul
EUR 235.2

Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Polyclonal Antibody
CAU22164-200ul 200ul
EUR 294

Breast cancer tissue array (Her-2: 3+/2+/1+/0)
BR082e each
EUR 78
Description: Breast cancer tissue array (Her-2: 3+/2+/1+/0), including pathology grade, TNM, clinical stage and IHC marker (ER, PR, Her-2 and Ki67), 4 cases/8 cores, replaced by BR082f

Multiple types breast cancer tissue array
BR1003a each
EUR 306
Description: Multiple types breast cancer tissue array, including pathology grade, TNM and clinical stage, 47 cases/101 cores, replacing BR1003

High-density breast cancer tissue array
BR6161 each
EUR 954
Description: High-density breast cancer tissue array, with stage, grade and normal breast tissue, 322 cases/616 cores

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) CLIA Kit
20-abx495288
  • EUR 9567.60
  • EUR 5095.20
  • EUR 1177.20
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Cancer Antigen CA 15-3 Protein (Human Milk)
VAng-Wyb8631-inquire inquire Ask for price
Description: CA 15-3 (Breast Cancer Antigen), Antigen Grade, Cancer antigen from Human Milk, 33.0 kIU/mL.

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit
20-abx150793
  • EUR 8853.60
  • EUR 4719.60
  • EUR 1093.20
  • 10 × 96 tests
  • 5 × 96 tests
  • 96 tests

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit
SEG768Hu-10x96wellstestplate 10x96-wells test plate
EUR 5677.8
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) in serum, plasma, tissue homogenates and other biological fluids.

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit
SEG768Hu-1x48wellstestplate 1x48-wells test plate
EUR 572.76
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) in serum, plasma, tissue homogenates and other biological fluids.

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit
SEG768Hu-1x96wellstestplate 1x96-wells test plate
EUR 766.8
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) in serum, plasma, tissue homogenates and other biological fluids.

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit
SEG768Hu-5x96wellstestplate 5x96-wells test plate
EUR 3090.6
Description: This is Double-antibody Sandwich Enzyme-linked immunosorbent assay for detection of Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) in serum, plasma, tissue homogenates and other biological fluids.

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit
4-SEG768Hu
  • EUR 5738.40
  • EUR 3031.20
  • EUR 768.00
  • 10 plates of 96 wells
  • 5 plates of 96 wells
  • 1 plate of 96 wells
Description: Enzyme-linked immunosorbent assay based on the Double-antibody Sandwich method for detection of Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) in samples from Serum, plasma, tissue homogenates and other biological fluids. with no significant corss-reactivity with analogues from other species.

Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit
EKN43917-48T 48T
EUR 378.7
Direct alteration of extracellular cues through in situ matrix softening reversed YAP exercise and the epigenetic program. Our findings recommend that epigenetic reprogramming of the mechanophysical properties of the extracellular microenvironment of stable tumours might symbolize a therapeutic technique for the inhibition of most cancers development.
Tagspcr pcr covid test pcr covid testing pcr kits price pcr test for coronavirus pcr test for covid 19 pcr testing for covid-19 pcr tests pcr unit pcram pcrb pcrdfans pcre pcrfy pcrfy stock pcrichard credit card pay bill pcrichard pay bill pcrichard&sons pcrichard.com pcrichardsandsons pcrm pcrx stock peptides and acids peptides anti-aging peptides collagen powder peptides definition peptides diet peptides for bodybuilding peptides for erectile dysfunction peptides for eyelash growth peptides for nerve repair peptides for sale peptides for skin peptides for weight loss peptides international peptides rodan and fields peptides serum peptides supplement peptides t3 peptides tadalafil peptides vs hgh peptides warehouse peptides warehouse scam peptidescience.com peptidesciences reagents coa reagents define reagents defined reagents definition reagents eso reagents for corona testing reagents for organic synthesis reagents nc reagents needed for covid-19 test reagents qc serums 76 serums anoka menu serums bar serums def serums fo76 serums for acne serums for hair serums for hair growth serums for men serums for sensitive skin serums for wrinkles serums in anoka serums in anoka mn serums mn serums osrs serums peru serums ulta serums vs creams serums with glycerin serums with spf serums.com serumstat

Leave a Reply

Your email address will not be published.